 Many epidemiological studies have shown that nutrients or elements from tomato or other plants, including lycopene and multi-carotenoids, may reduce the risk of prostate cancer, especially those of lethal cancer. Studies have also shown that multi-carotenoids may reduce serum PSA levels in prostate cancer patients. MCS is a patented, multi-carotenoids-rich, purely botanic agent. The investigators previous Phase II and III clinical trials US FDA and TFDA, 600 subjects, studies finished, data in analysis have shown that there were no MCS-related serious adverse events SAE. MCS may relieve urinary symptoms in men with BPH and PSA was reduced in men with elevated PSA. So, the investigators are initiating a large multi-center phase II randomized study MCS-8, N702 in Taiwan, to study if MCS can reduce the risk of prostate cancer. High risk patients will be assigned to take oral daily 30, 15, and 0 placebo mg of MCS 1:1:1. The investigators will compare the cumulative prostate cancer incidence among groups and the change from baseline in serum carotenoids levels. 